XTNT Earnings Prediction
The chart below shows how XTNT performed 10 days before and after its earnings report, based on data from the past quarters. Typically, XTNT sees a +11.72% change in stock price 10 days leading up to the earnings, and a -7.87% change 10 days following the report. On the earnings day itself, the stock moves by -2.83%. This data can give you a slight idea of what to expect for the next quarter's release.
XTNT Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
--
--
--
No Data Available
XTNT Earnings Analysis
Xtant Medical Holdings Inc Corporation (XTNT.A) Earnings Conference Call
Positive
Fourth-Quarter Revenue Surge: Record fourth-quarter revenue of $31.5 million, marking a 12% growth quarter over quarter and a 28% year-over-year growth.
Positive Adjusted EBITDA Achievement: Achieved positive adjusted EBITDA of $438,000 in Q4 2024, despite a $1.5 million inventory write-off related to the Surgiline acquisition.
Positive Cash Flow Achievement: Generated cash flows from operations in Q4 of over half a million dollars for the first time since 2022.
Operating Expense Reduction: Reduced operating expenses by approximately $5 million since August 2024, primarily through headcount reductions of over 13%.
Biologics Business Expansion: Biologics business grew 21% for the year, driven by the successful launch of the OsteoVide Plus stem cell offering and the new Ambion product line.
New Biologics Product Launch: Anticipated launch of four new biologics products in 2025, including a growth factor product that will enhance the current offering.
Q Code Licensing Revenue: Licensed a Q code for the single-layer Amneon product, resulting in an upfront licensing fee of $1.5 million.
Biologics Revenue Growth Outlook: Expecting mid-double-digit revenue growth in Biologics for 2025, while projecting modestly down revenue year over year in hardware.
2025 Revenue Guidance: Guidance for full year 2025 revenue is projected to be between $126 million to $130 million, representing an 8% to 11% growth.
Negative
Earnings Miss Report: Xtant Medical Holdings, Inc. missed earnings expectations with a reported EPS of $-0.02, compared to expectations of $-0.01.
Gross Margin Decline: The gross margin for Q4 2024 was 50.8%, a significant decline from 61% in Q4 2023, primarily due to a $1.5 million inventory write-off and reduced yields.
High Operational Costs: Operating expenses for Q4 2024 were $17.9 million, which, while lower than the previous year, still represented 56.8% of total revenue, indicating high operational costs relative to revenue.
Net Loss Improvement: The company reported a net loss of $3.2 million in Q4 2024, an improvement from a loss of $4.3 million in Q4 2023, but still indicative of ongoing financial challenges.
Net Loss Comparison: For the full year 2024, the net loss was $16.4 million, a stark contrast to a net income of $660,000 in 2023, highlighting a significant downturn in profitability.
EBITDA Loss Worsens: Adjusted EBITDA for 2024 was a loss of $2.3 million, worsening from a loss of $1.4 million in 2023, indicating ongoing struggles to achieve profitability despite revenue growth.
Hardware Sales Decline: The hardware segment experienced a 10% decline in sales, attributed to previous year comparisons and ongoing EU supply chain issues, which negatively impacted international sales.
XTNT FAQs
How does XTNT typically perform around its earnings report dates?
Is Xtant Medical Holdings Inc (XTNT) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
XTNT Earning Call Sentiment
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2024 Earnings Call Transcript
XTNT.A
-0.54%Positive
The company's earnings call highlights both positive and negative factors. While there is a revenue increase and strong growth in biologics, concerns arise from declining hardware sales, a net loss, and supply chain issues. The lack of a share buyback or dividend program also limits positive sentiment. Furthermore, the Q&A session reveals uncertainties regarding product launches and growth potential. The combination of these factors suggests a neutral stock price movement in the short term, as improvements are offset by risks and uncertainties.
